Veronica Conca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Veronica Conca has a total of 314 co-authors. Here are the top co-authors by number of shared publications:
- Chiara Cremolini
Department of Oncology, University Hospital of Pisa, Pisa, Italy
70 shared publications - Filippo Pietrantonio
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
66 shared publications - Francesca Bergamo
Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
47 shared publications - Sabina Murgioni
Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
41 shared publications - Alessandra Boccaccino
Medical Oncology, Santa Maria delle Croci hospital, Ravenna AUSL Romagna, ITALY
36 shared publications - Alessandro Passardi
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
36 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Table S3 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Table S3 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Table S1 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Table S1 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Table S2 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Table S2 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Purpose:Resection of liver metastases improves survival in patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD), but relapse remains common. Postresection circulating tumor DNA (ctDNA) is a valid prognostic biomarker; however, no data are available regarding the prognostic effect of presurgery ctDNA after upfront chemotherapy.Experimental Design:Patients (N = 116) with initially unresectable mCRC with LLD who underwent resection after upfront chemotherapy were included. Patients were sequenced with a tumor-naïve ctDNA-based minimal residual disease (MRD) assay at baseline (before chemotherapy), before surgery, and after surgery.Results:Presurgery ctDNA status was not significantly associated with relapse-free survival (RFS). However, exploratory analyses demonstrated that a ≥50% reduction in variant allele frequency from baseline to before surgery was independently associated with improved RFS (median RFS: 21.0 vs. 9.8 months; HR: 2.19; P = 0.014), aligned with multivariate analysis (P = 0.022). Postsurgery ctDNA positivity was strongly predictive of recurrence (HR: 6.66; P < 0.001), with 100% specificity and 56.4% sensitivity. ctDNA dynamics from before to after surgery further stratified recurrence risk, regardless of adjuvant chemotherapy status. ctDNA dynamics from before to after surgery further stratified recurrence risk. Quantitative ctDNA measures (predicted tumor fragments per million) also correlated with RFS.Conclusions:Use of a tumor-naïve MRD assay increased the accuracy of detecting ctDNA after chemotherapy treatment, when a significant drop of ctDNA amount is expected compared with tests routinely used in metastatic disease. Presurgery ctDNA dynamics were prognostic with respect to RFS and may help stratify patients’ prognosis prior to resection, potentially informing personalized treatment decisions.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
Purpose:Resection of liver metastases improves survival in patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD), but relapse remains common. Postresection circulating tumor DNA (ctDNA) is a valid prognostic biomarker; however, no data are available regarding the prognostic effect of presurgery ctDNA after upfront chemotherapy.Experimental Design:Patients (N = 116) with initially unresectable mCRC with LLD who underwent resection after upfront chemotherapy were included. Patients were sequenced with a tumor-naïve ctDNA-based minimal residual disease (MRD) assay at baseline (before chemotherapy), before surgery, and after surgery.Results:Presurgery ctDNA status was not significantly associated with relapse-free survival (RFS). However, exploratory analyses demonstrated that a ≥50% reduction in variant allele frequency from baseline to before surgery was independently associated with improved RFS (median RFS: 21.0 vs. 9.8 months; HR: 2.19; P = 0.014), aligned with multivariate analysis (P = 0.022). Postsurgery ctDNA positivity was strongly predictive of recurrence (HR: 6.66; P < 0.001), with 100% specificity and 56.4% sensitivity. ctDNA dynamics from before to after surgery further stratified recurrence risk, regardless of adjuvant chemotherapy status. ctDNA dynamics from before to after surgery further stratified recurrence risk. Quantitative ctDNA measures (predicted tumor fragments per million) also correlated with RFS.Conclusions:Use of a tumor-naïve MRD assay increased the accuracy of detecting ctDNA after chemotherapy treatment, when a significant drop of ctDNA amount is expected compared with tests routinely used in metastatic disease. Presurgery ctDNA dynamics were prognostic with respect to RFS and may help stratify patients’ prognosis prior to resection, potentially informing personalized treatment decisions.
- 4 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (23) , 2255-2257
Reply to: “Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in TRIPLETE Study” and “TRIPLETE But Incomplete? Accounting for Post-Progression Therapy When Interpreting Overall Survival”
- 4 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (23) , 2255-2257
Reply to: “Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in TRIPLETE Study” and “TRIPLETE But Incomplete? Accounting for Post-Progression Therapy When Interpreting Overall Survival”